TROV


Maxim Reiterates Upbeat View of TrovaGene Inc Following Positive HPV HR Test Data

Maxim’s healthcare analyst Jason Kolbert came out with a positive commentary on TrovaGene Inc (NASDAQ:TROV), following the news that the company’s urine-based HPV HR Test is equally capable of detecting …

Cantor Initiates Buy on TrovaGene Inc; Sees 56% Upside for the Stock

In a research report published yesterday, Cantor analyst Bryan Brokmeier initiated coverage on shares of TrovaGene Inc (NASDAQ:TROV) with a Buy rating and price …

Stock Update (NASDAQ:TROV): TrovaGene Inc Forms European Institute with Alberto Bardelli, Ph.D.; Core Technologies Transferred from University of Torino

TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced today the establishment of Trovagene Research Institute (TRI), a European subsidiary focused on expanding …

Stock Update (NASDAQ:TROV): TrovaGene Inc’s Urine-Based Liquid Biopsy Platform Shown to Detect Impact of Cancer Therapy within 24 Hours

TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced today that clinical data featuring its Precision Cancer Monitoring℠ platform will be presented at …

Stock Update (NASDAQ:TROV): TrovaGene Inc to Present Clinical Data and Capabilities of Its Urine-Based Liquid Biopsy Platform at the 7th Annual Next Generation Dx Summit

TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced today that clinical data featuring its Precision Cancer Monitoring℠ platform will be presented at …

Company Update (NASDAQ:TROV): TrovaGene Inc Announces Pricing of Public Offering of Common Stock

TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock. …

Stock Update (NASDAQ:TROV): TrovaGene Inc Announces Public Offering of Common Stock

TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced that it is offering to sell shares of its common stock in an …

Maxim Pounds the Table on TrovaGene Inc (TROV)

Maxim Group analyst Jason Kolbert was out pounding the table on TrovaGene Inc (NASDAQ:TROV) Thursday, reiterating a Buy rating and price target of $13, …

Cantor Reiterates Buy on TrovaGene Inc Following Data Presentations

In a research report issued today, Cantor analyst Sung Ji Nam reiterated a Buy rating on TrovaGene Inc (NASDAQ:TROV) with an $8 price target, after several …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts